Regeneron Pharmaceuticals Inc (REGN)

The $639 million deal marks the the third purchase for Brent Saunders since early August.

The most recent short interest data has been released for the 08/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) said today that trials of their cholesterol drug Praulent met targets.

Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.

A component of Regeneron's Rapid Response program, which is also targeting Zika and Ebola

The most recent short interest data has been released for the 07/29/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AVG, CIT, CRNT, CX, EGL, FOE, GOOD, ISNS, KRNT, KTEC, LBY, LPX, MIXT, MPC, MTSI, NATR, NVTA, REGN, SSTK Downgrades: CBPX, DVA, FCFP, ITG, PBH, STN Initiations: CFMS, JCAP, LILA, LILAK, NIHD, PYPL Read on to get TheStreet Quant Ratings' detailed report:

Cramer shares his views on the winners and losers of this earnings season. Comcast, Idexx Laboratories and Zoetis are among the stocks discussed.

Trade-Ideas LLC identified Regeneron Pharmaceuticals (REGN) as an unusual social activity candidate

With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.

The two Big Pharma giants are looking for new ways to drive growth through anti-cancer treatments.

The new deals signal a long-term commitment from two of the largest biotech companies to focus on cancer immunotherapy as a platform for future growth.

Regeneron and Adicet to pursue "off-the-shelf" cellular therapies in oncology

TheStreet highlights 3 stocks pushing the health care sector higher today.

That may be the best way to get through the notorious month of August.

Utilities and other high yielding sectors are reaching overbought levels, so investors may want to rotate into biotechs, says Jim Cramer.

The biotech sector was a great short throughout the year, but that trade appears to be over, Cramer said.

Investors should risk below $380 for now.

The most recent short interest data has been released for the 07/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Cramer is gearing up for the heaviest week of this earnings season, but he's also providing his game plan for helping you be a better investor.

TheStreet highlights 3 stocks pushing the health care sector higher today.

TheStreet highlights 3 stocks pushing the health care sector lower today.

The most recent short interest data has been released for the 06/30/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.